19th August 2022

Ineligible Shareholder Letter

Ineligible Shareholders - Paradigm Biopharmaceutical Limited Rights Issue Offer

Dear Shareholder,

On 15 August 2022 Paradigm Biopharmaceutical Limited (**Company**) announced that it is undertaking a non-renounceable pro-rata entitlement offer of 1 New Share (**New Share**) for every 15 Shares held at the Record Date of 7.00pm (AEST) on 18 August 2022, at an Issue Price of $1.30 per New Share to raise approximately $20.3 million (before costs) (**Offer**), on the basis that no more than approximately 15.6 million New Shares will be issued pursuant to the Offer.

The Offer is being made without a prospectus or other disclosure document in accordance with section 708AA of the Corporations Act. A copy of the above announcements, with further details of the Offer, is available on the Company's website (https://paradigmbiopharma.com) and also on the ASX Announcement Platform. A copy of the Rights Issue Offer Document is expected to be lodged with the ASX and available for viewing on the ASX website and the Company's website (https://paradigmbiopharma.com) on or around 22 August 2022.

As permitted by law, the Company has decided that it is unreasonable to make the Offer to any Shareholder with a registered address outside Australia or New Zealand or Hong Kong as at the Record Date (namely 18 August 2022), having regard to:

(a) the number of Shareholders with addresses in such other countries as a proportion of total Shareholders in the Company;

(b) the number and value of the Shares those Shareholders would be offered under the Offer; and

(c) the cost to the Company of complying with applicable legal and regulatory requirements in such other countries.

This letter is to inform you that under the terms of the Offer, you are an ineligible shareholder and therefore not eligible to subscribe for New Shares and no entitlements will be issued to you. This letter is not an offer to issue New Shares or entitlements to you, nor an invitation for you to apply for New Shares.

If you have any questions concerning the Offer, please call the Company's share registry, on 1300 521 172 (within Australia) or +61 3 9415 4644 (outside Australia) between 8.30 am to 5.30 pm AEST Monday to Friday during the Offer period

For other questions, you should contact your stockbroker, accountant, taxation advisor, financial advisor or other professional advisor.

Yours faithfully



Kevin Hollingsworth
Company Secretary
For and on behalf of the Board of Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins Street, Melbourne, VIC, 3000, AUSTRALIA

For more information please head to: www.paradigmbiopharma.com

Important Information

This letter is for information purposes only and does not constitute an offer, invitation or recommendation to subscribe for, retain or purchase any securities in the Company in any jurisdiction. This letter does not constitute financial product advice and does not and will not form part of any contract for the acquisition of shares in the Company.

This letter does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. No action has been made or will be taken to register, qualify or otherwise permit a public offering of the New Shares in any jurisdiction outside Australia or New Zealand. In particular, neither the entitlements nor the New Shares have been, or will be, registered under the U.S. Securities Act, as amended (the "**Securities Act**") or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Entitlements may not be exercised or taken up by, and the New Shares may not be offered or sold to, persons in the United States or persons who are acting for the account or benefit of persons in the United States unless they are offered and sold in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws.

Certain statements made in this letter are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about the industry in which the Company operates, and beliefs and assumptions. Words such as "anticipates", "expects", "intends", "plans", "believes", "seeks", "estimates", and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this letter. The forward-looking statements made in this letter relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this letter except as required by law or by any appropriate regulatory authority.